Skip to content


  • Meeting abstract
  • Open Access

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer

  • TI Andersen1, 3,
  • E Skovlund4,
  • IK Bukholm3,
  • U Jacobsen2,
  • R Kåresen2,
  • B Erikstein4,
  • J Nesland5 and
  • A-L Børresen-Dale3
Breast Cancer Research20002(Suppl 1):P3.07

Published: 12 March 2000


Breast CancerBreast CarcinomaGene AmplificationHuman Breast CarcinomaTP53 Status

Full text

Activation of the HER-2 proto-oncogene and inactivation of the TP53 tumour-suppressor gene belong to the most common genetic changes in human breast carcinomas. Both appear to be of prognostic significance, at least in patients with node-positive disease. The relevance of these changes in node-negative disease, however, still remains uncertain. Moreover, the relationship between HER-2 and TP53 status remains to be fully clarified.

HER-2 and TP53 status were determined in 261 breast carcinomas collected from Norwegian breast cancer patients diagnosed between 1984 and 1994. HER-2 status was determined using immunohistochemistry. A subset of the tumours was also examined with regard to gene amplification using the Southern blot technique. A significant association was found between the presence of gene amplification and positive HER-2 immunostaining in the tumour. The tumours were also examined for TP53 alterations using CDGE (constant denaturant gel electrophoresis) and immunohistochemistry. A significant association was found between the presence of HER-2 activation and TP53 inactivation in the tumour. Survival analyses will be presented.

Authors’ Affiliations

Departments of Oncology, Norway
Surgery, Ullevål University Hospital, Oslo, Norway
Departments of Genetics, Norway
Oncology, Norway
Pathology, The Norwegian Radium Hospital, Oslo, Norway


© Current Science Ltd 2000